Market News AIOpen the app

Ultragenyx Pharmaceutical says it reached a deal with Navinta to let them sell a generic version of DOJOLVI.

RulesRead the original at SEC EDGAR
Bad for RARE

The license lets Navinta sell DOJOLVI generically without royalties starting in 2033, creating future competition. The date is distant and other cases remain pending, but this agreement gives one competitor a path to market.

RARE · Ultragenyx Pharmaceutical Inc.

AI read · Bad for RARE

The AI's read

DOJOLVI could face a generic rival without royalty payments once the license starts. The start date is years away, and similar cases against other applicants remain open. Still, this agreement gives one competitor a route to market.

Get alerts for RARE

Follow Ultragenyx Pharmaceutical Inc. (RARE) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for RARE
Free on the App Store and Google Play, or on the web.